Abbott's Freestyle Libre 2 Ios App Cleared In U.S

FreeStyle Libre 2 iOS app is the only sensor-based glucose monitoring app that allows users to check their glucose with a compatible iPhone every minute with optional real-time glucose alarms

Abbott announced today that the U.S. Food and Drug Administration (FDA) has cleared the FreeStyle® Libre 2 iOS application for use with compatible iPhones1, providing a comprehensive digital offering for its FreeStyle Libre 2 integrated continuous glucose monitoring (iCGM) system. Providing breakthrough technology that is accessible and affordable4, the FreeStyle Libre portfolio is the number one continuous glucose monitoring (CGM) system worldwide and most prescribed in the U.S. changing the lives of nearly 3.5 million people across more than 50 countries including 1 million users in the U.S.

Approved for adults and children (4 and older) with diabetes, the new FreeStyle Libre 2 app creates a seamless experience for users and healthcare professionals. The app enables users to get glucose readings directly on their iPhones without the use of a reader. A key benefit of the app is the ability for caregivers to remotely monitor their loved one's glucose readings and get real-time alarms via the LibreLinkUp app.7

According to Jared Watkin, senior vice president, Diabetes Care, Abbott "The demands of living with diabetes can be overwhelming, and there's a critical need to improve the way people with diabetes manage their condition – easily, affordably, accurately – and in a way that seamlessly fits into their everyday lives, The FreeStyle Libre 2 iOS app streamlines how people manage their diabetes on their iPhones – empowering users with the information they need 24/7 while improving their health on the go."

With a 14-day wear time, FreeStyle Libre 2 is the longest-lasting iCGM sensor currently on the market.9 Available at pharmacies at a fraction of the cost of other CGM systems,10 the FreeStyle Libre 2 system is widely accessible to people with diabetes. Integrated features include:

Optional real-time glucose alarms that automatically alert users when glucose is high or low

Unsurpassed 14-day accuracy with readings every minute and an eight-hour glucose history, including a comprehensive view of trends

Seamless integration with Abbott's connected digital health tools – the LibreLinkUp app and LibreView12, a secure cloud-based data management platform – allowing users to easily share their glucose readings with healthcare professionals and caregivers. Accessible remotely, the use of LibreView increased about 70% over the past year.13

Abbott has secured partial or full reimbursement for the FreeStyle Libre system in 38 countries, including Canada, France, Germany, Japan, the United Kingdom, and the U.S.

The FreeStyle Libre 2 iOS app will be available soon in the U.S. to download on the App Store.